Compare Vale SA (VALE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs Vertex Pharmaceuticals Incorporated — how do they compare? Vale SA trades at $14.43 (market cap $61.97B), while Vertex Pharmaceuticals Incorporated trades at $527.7 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× Vale SA's market cap, and Vale SA pays a 8.35% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VALE | VRTX | |
|---|---|---|
Market Cap | $61.97B | $134.25B |
Sector | Basic Materials | Health |
52-Week High | $17.82 | $529.65 |
52-Week Low | $9.71 | $376.62 |
Enterprise Value | $78.22B | $128.37B |
Dividend Yield | 8.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vale S.A. (VALE) trades at $14.89, up 1.22% today, with a neutral technical stance. The company reported Q2 2026 EPS of $0.36, missing estimates of $0.41, continuing a trend of earnings misses. Revenue for 2025 was $38.40B, with net income margin at 5.11%. Cash flow from operations remains strong at $8.80B for 2025, supporting a $0.40 dividend scheduled for payment in September 2026.
The outlook is mixed: analyst consensus price target is $16.79 (12.8% upside), but rising costs and earnings misses pose risks. Base metals growth offers opportunity, yet iron ore volatility and debt increases require monitoring. The stock presents value with a P/E of 28.64 and EV/EBITDA of 7.65, but investor caution is warranted given recent performance.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
